The aim of this randomized controlled clinical study is to clinically evaluate the efficacy of topical applications of 0.1% Tacrolimus ointment (TacrozTM
-Forte), when compared with 0.1% Mometasone furoate ointment (MomtasTM
), in the management of erosive or ulcerative oral lichen planus
Materials and Methodology: The study population consisted of 30 patients with oral erosive or ulcerative lichen planus randomized into two groups. Group I applied 0.1% Tacrolimus ointment (TacrozTM-Forte), where as group II applied 0.1% Mometasone furoate ointment (MomtasTM) twice daily to their oral lesions for 6 weeks and the patients were followed for 8 weeks after active treatment. In the clinical analysis the parameters evaluated included, erythema, ulceration, size of the lesion and severity of pain on a Visual Analogue Pain scale (VAS).
Results: Group I showed statistically significant improvement in ulceration, erythema, and VAS scores when compared to group II from baseline to subsequent recall appointments. 2 patients did not respond to 0.1% topical Mometasone furoate. At 8 weeks of post treatment period recurrence of erythema was observed in 7 patients (46.67%) in group I and 6 patients (50%) in group II. No severe adverse effects were observed in both groups, except for transient burning sensation at the site of application of the drug and dryness of the mouth in few patients.
Conclusion: Both 0.1% topical Tacrolimus and 0.1% Mometasone furoate are effective in the treatment of erosive or ulcerative OLP. The clinical efficacy of 0.1% topical Tacrolimus is observed to be superior to that of 0.1% Mometasone furoate.